Genmab — December 2019
-
Updated analysis of MAIA: D-Rd continues to beat Rd in transplant-ineligible NDMM https://www.youtube.com/watch?v=NfBDpLjI2mM
-
-
from Q&A - Jan Van de Winkel We will present a very impressive preclnical data set at the ASH conference in early
December showing that HexaBody CD38 can effectively kill tumors that are not
sensitive to Daratumumab...
Jan Van de Winkel A number of tumors will be presented in Orlando and we certainly think that HexaBody
CD38 could well provide an option for treatment of solid cancers.
-CD3xCD20 (GEN3013) study as well as various daratumumab studies presented at the 61st Annual Meeting of the American Society of Hematology (ASH).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind